Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Am J Reprod Immunol ; 82(2): e13149, 2019 08.
Article in English | MEDLINE | ID: mdl-31099938

ABSTRACT

PROBLEM: Recently, interleukin (IL)-32 has been suggested to be involved in the pathogenesis of endometriosis. The aim of this study was to investigate whether serum IL-32 level might be used as a biomarker for diagnosis of endometriosis. METHOD OF STUDY: We recruited the serum samples of 50 patients with histologically confirmed endometriosis and 35 controls. Enzyme-linked immunosorbent assay was used to analyze the serum IL-32, IL-6, IL-10, tumour necrosis factor (TNF)-α, IL-1ß, and CA-125 levels in patients with and without the disease and the diagnostic potentials of the cytokines were assessed using receiver operating characteristic curve and the area under the curve (AUC). RESULTS: Among evaluated cytokines, only serum IL-32 levels showed significant differences between patients with and without endometriosis (1111.24 ± 149.59 vs 631.10 ± 120.23 ng/mL, P = 0.018, respectively). When the diagnostic power of serum IL-32 was evaluated, the AUC was 0.638 (95% confidence interval (CI): 0.521-0.766, P = 0.031). When serum IL-32 levels were combined with serum CA-125 levels, the AUC was increased to 0.749 (95% CI: 0.640-0.858, P < 0.001) with sensitivity and specificity of 60.0% and 82.9% at cutoff value of 0.640, which led to detect 25 more cases of endometriosis than the use of serum CA 125 with the cutoff value of 35 IU/mL (36/50 vs 11/50, P < 0.001) without sacrificing the specificity of the marker. CONCLUSION: Serum IL-32 levels are elevated in patients with endometriosis, and with combination of serum CA-125 levels, it may serve as a potential biomarker for endometriosis.


Subject(s)
Endometriosis/blood , Endometriosis/diagnosis , Interleukins/blood , Adult , Area Under Curve , Biomarkers/blood , CA-125 Antigen/blood , CA-125 Antigen/metabolism , Cross-Sectional Studies , Endometriosis/metabolism , Female , Humans , Interleukin-10/blood , Interleukin-10/metabolism , Interleukin-1beta/blood , Interleukin-1beta/metabolism , Interleukin-6/blood , Interleukin-6/metabolism , Interleukins/metabolism , ROC Curve , Sensitivity and Specificity , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/metabolism
2.
Phytother Res ; 30(5): 691-700, 2016 May.
Article in English | MEDLINE | ID: mdl-26887532

ABSTRACT

Systematic reviews and meta-analyses represent the uppermost ladders in the hierarchy of evidence. Systematic reviews/meta-analyses suggest preliminary or satisfactory clinical evidence for agnus castus (Vitex agnus castus) for premenstrual complaints, flaxseed (Linum usitatissimum) for hypertension, feverfew (Tanacetum partenium) for migraine prevention, ginger (Zingiber officinalis) for pregnancy-induced nausea, ginseng (Panax ginseng) for improving fasting glucose levels as well as phytoestrogens and St John's wort (Hypericum perforatum) for the relief of some symptoms in menopause. However, firm conclusions of efficacy cannot be generally drawn. On the other hand, inconclusive evidence of efficacy or contradictory results have been reported for Aloe vera in the treatment of psoriasis, cranberry (Vaccinium macrocarpon) in cystitis prevention, ginkgo (Ginkgo biloba) for tinnitus and intermittent claudication, echinacea (Echinacea spp.) for the prevention of common cold and pomegranate (Punica granatum) for the prevention/treatment of cardiovascular diseases. A critical evaluation of the clinical data regarding the adverse effects has shown that herbal remedies are generally better tolerated than synthetic medications. Nevertheless, potentially serious adverse events, including herb-drug interactions, have been described. This suggests the need to be vigilant when using herbal remedies, particularly in specific conditions, such as during pregnancy and in the paediatric population. Copyright © 2016 John Wiley & Sons, Ltd.


Subject(s)
Herb-Drug Interactions , Phytotherapy/adverse effects , Phytotherapy/methods , Plant Extracts/adverse effects , Female , Humans
3.
Arch Argent Pediatr ; 109(4): e82-4, 2011 08.
Article in Spanish | MEDLINE | ID: mdl-21829863

ABSTRACT

Tungiasis, is a cutaneous parasitosis, native of America caused by Tunga penetrans. Infestations usually presents with black papular lesions, either single or multiple, most of them localized on the feet, mainly in the subungual and periungual areas. Diagnosis of tungiasis is based on the characteristic aspect of the lesions in a patient coming from an endemic area. Surgical removal of the flea and application of a topical antibiotic is the standard treatment. We describe a case of a 10-years-old girl, with multiple lesions localized on feet, who was succesfully treated with ivermectin and surgical removal of lesions.


Subject(s)
Tungiasis , Child , Female , Humans , Tungiasis/diagnosis , Tungiasis/drug therapy
4.
Arch. argent. pediatr ; 109(4): e82-e84, jul.-ago. 2011. ilus
Article in Spanish | LILACS | ID: lil-633191

ABSTRACT

La tungiasis es una parasitosis cutánea originaria de América causada por Tunga penetrans. Se caracteriza por lesiones papulares, negruzcas, únicas o múltiples, que suelen afectar los pies, principalmente en las zonas subungueales y periungueales. El diagnóstico de tungiasis se realiza por las características clínicas de las lesiones en un paciente proveniente de zonas endémicas. El tratamiento de elección es la extracción quirúrgica de la pulga y la aplicación de antibióticos tópicos. Presentamos un caso de tungiasis en una paciente de 10 años de edad con múltiples lesiones en ambos pies, que fue tratada satisfactoriamente con ivermectina y extracción quirúrgica.


Tungiasis, is a cutaneous parasitosis, native of America caused by Tunga penetrans. Infestations usually presents with black papular lesions, either single or multiple, most of them localized on the feet, mainly in the subungual and periungual areas. Diagnosis of tungiasis is based on the characteristic aspect of the lesions in a patient coming from an endemic area. Surgical removal of the fea and application of a topical antibiotic is the standard treatment. We describe a case of a 10-years-old girl, with multiple lesions localized on feet, who was succesfully treated with ivermectin and surgical removal of lesions.


Subject(s)
Child , Female , Humans , Tungiasis , Tungiasis/diagnosis , Tungiasis/drug therapy
6.
Gynecol Oncol ; 96(2): 500-3, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15661242

ABSTRACT

OBJECTIVE: To improve clinical prospects by reducing intraoperative or postoperative complications, subsequent hysterectomy is generally conducted within 48 h or 6 weeks after cervical cold-knife conization. The loop electrosurgical excision procedure (LEEP) is widely used for cervical conization. However, no study has ever been undertaken on the relation between postoperative sequelae and the time between LEEP and hysterectomy. Therefore, this study was undertaken to evaluate the correlations between postoperative sequelae and the interval between LEEP and hysterectomy. METHODS: The medical records of 338 patients, who underwent type 1 extended hysterectomy after LEEP at the Department of Obstetrics and Gynecology, Yonsei University College of Medicine, were retrospectively reviewed. The subjects were divided into three groups according to time from LEEP to hysterectomy: group 1 (within 48 h, n = 210), group 2 (between 48 h and 6 weeks, n = 88), and group 3 (>6 weeks, n = 40). RESULTS: The three groups showed no significant differences with respect to patient characteristics (age, delivery history, body mass index, and a history of surgery). Postoperative complications such as fever, dysuria, and surgical region complications (effraction, infection, and rubefaction) were not significantly different among the three groups. Other complications, namely, ureter injury and abdominal wall hematoma, were found in one case in each group 1. CONCLUSION: The postoperative clinical courses were not significantly different regardless of time interval between LEEP and subsequent hysterectomy. Therefore, hysterectomies can be conducted at any time when the patient is in an appropriate condition, i.e., not precisely within 48 h or >6 weeks after LEEP.


Subject(s)
Electrosurgery/methods , Hysterectomy/methods , Uterine Cervical Dysplasia/surgery , Uterine Cervical Neoplasms/surgery , Adult , Conization/methods , Female , Humans , Middle Aged , Morbidity , Neoplasm Staging , Retrospective Studies , Time Factors , Uterine Cervical Neoplasms/pathology , Uterine Cervical Dysplasia/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...